COVERAGE HUB
$SPRO
2 articles in last 30 days
LAST 30 DAYS
2 articles
AVG GRADE
HIGH
score: 0.75
SENTIMENT
BULLISH
TOTAL VIEWS
1
RECENT COVERAGE · 2 ARTICLES
Spero Therapeutics: Yesterday's Selloff On Utebzi Approval Seems Bewildering (NASDAQ:SPRO)
SPRO received FDA approval for Utebzi, a development milestone typically considered positive for biotech firms. The approval unlocks...
Utebzi (tebipenem pivoxil) approved in the US for adults with complicated urinary tract infections (cUTIs)
SPRO and GSK achieved a significant regulatory milestone with FDA approval of Utebzi, the first and only oral carbapenem antibiotic for...
RELATED TICKERS